Our Group in numbers
One group. Three stories.
Millions of patients served.
Novasep CDMO strengthens its innovative position in oncology
We invested €8 million in our Le Mans (Fr) site to expand our production capabilities for manufacturing ADCs. Behind every pharma project, there are high-quality services for our customers and cutting-edge drugs for millions of patients worldwide.
Combining strengths to provide existing and innovative treatments for patients
“Axplora possess a unique blend of technical expertise (chromatography and small molecule manufacturing), interpersonal skills, and a dedication to excellence that makes them an exceptional CMO. We are fortunate to have such a strong partnership with the Axplora team!”

“The Axplora team was very open, flexible and efficient in working through project changes.”

Martin Meeson - CEO
DCAT Value Chain Insights - Industry Roundtable: Small-Molecule APIs - January 2025
"The continued rising demand for complex APIs, particularly in areas such as GLP-1 receptor agonists for metabolic disorders and antibody-drug conjugates (ADCs) for oncology, increases the need for advanced manufacturing expertise and specialized facilities."

Axplora in the news

Axplora announces €50 Million Investment in GLP-1 Manufacturing at Mourenx (France) Site

Martin Meeson appointed as CEO of Axplora
